No Data
Biosino Bio-Tec (08247) plans to appoint RSM Hong Kong as the auditor.
biosino bio-tec (08247) announced that due to the company's inability to reach an agreement with Ernst & Young by December 2024...
Biosino Bio-Tec (08247.HK): The loss attributable to the parent company in the first half of the year was 13.182 million yuan.
Biosino bio-tec (08247.HK) announced on August 29 that it achieved revenue of 0.134 billion yuan for the six months ended June 30, 2024, a decrease of 3.8% year-on-year. The gross profit was 58.531 million yuan, a decrease of 12.2% year-on-year. The loss attributable to the owners of the parent company was 13.182 million yuan, compared to a loss of 5.423 million yuan in the same period of the previous year. The basic loss per share was 0.091 yuan.
BIOSINO BIO-TEC: Interim Report 2024
BIOSINO BIO-TEC: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
China Securities Co., Ltd.: Q2 albumin batch issuance is the same as last year, and hepatitis B batch issuance has resumed growth.
The blood product industry is expected to maintain steady growth in the first half of 24H1. In the second half of the year, the industry is expected to continue the tight supply and demand pattern. The leading companies in the industry are expected to achieve continuous increase in plasma collection and profitability, and have more competitive advantages.
Little Excitement Around Biosino Bio-Technology and Science Incorporation's (HKG:8247) Revenues As Shares Take 31% PoundingNo Data
No Data
